Home › Funds › J. Stern & Co. LLP › ABT

J. Stern & Co. LLP position in ABT

ABBOTT LABORATORIES · Health Care

J. Stern & Co. LLP reported holding 247,689 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$24.5M, representing 2.53% of its reported portfolio and ranking #17 among its reported holdings. J. Stern & Co. LLP has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)247.69K sh
Reported value held$24.48M
Portfolio Weight2.53%
First reportedQ4 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How J. Stern & Co. LLP's ABT position evolved

J. Stern & Co. LLP first disclosed a stake in ABT in Q4 2023 at 211,927 shares (US$24.0M). The position peaked in Q2 2025 at 351,707 shares, worth US$46.8M. Across 11 filings, J. Stern & Co. LLP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 247,689 shares valued at US$24.5M — a reduction of -63,540 shares quarter over quarter.. Notable position changes include a 12440% increase in Q4 2025 (shares fell 18% over the following quarter), a 99% trim in Q1 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 211.93K $23.98M New
Q2 2024 295.16K $30.67M New
Q3 2024 299.13K $34.10M Add
Q4 2024 315.43K $35.68M Add
Q1 2025 340.79K $45.21M Add
Q2 2025 351.71K $46.78M Add
Q3 2025 313.56K $42.00M Reduce
Q4 2025 39.32M $39.32M Add
Q1 2026 315.96K $32.44M Reduce
Q2 2026 311.23K $28.24M Reduce
Q3 2026 247.69K $24.48M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.65B), Charles Schwab Investment Management (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has J. Stern & Co. LLP held ABT?

J. Stern & Co. LLP has disclosed ABT holdings in 11 of the last 12 reported quarters, going back to Q4 2023.

What is J. Stern & Co. LLP's current position in ABT?

As of Q3 2026, J. Stern & Co. LLP holds 247.69K shares of ABT (ABBOTT LABORATORIES), valued at $24.48M, representing 2.53% of its reported portfolio and ranking #17.

Has J. Stern & Co. LLP been buying or selling ABT?

In the latest 13F filing (Q3 2026), J. Stern & Co. LLP reduced its position in ABT. The position peaked in Q2 2025 at 351.71K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, Charles Schwab Investment Management, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.